We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > PD-1 inhibitor

News List

Tyvyt (Sintilimab Injection), an Innovative PD-1 Inhibitor Jointly Developed by Innovent and Lilly, is Included in the New Catalogue of National Reimbursement Drug List (NRDL) En-CPhI.CN
December 02, 2019
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops and commercializes high quality medicines for the treatment of oncology ...
Merck gets FDA okay for Keytruda as liver cancer therapy pharmaphorum
December 12, 2018
Merck & Co/MSD has won approval in the US for PD-1 inhibitor Keytruda as a treatment for hepatocellular carcinoma (HCC), the most common form of liver cancer, opening up another front in its rivalry with Bristol-Myers Squibb.....
BMS(nivolumab) now the first and only FDA-approved PD-1 inhibitor of every four-week dosing worldpharmanews
March 12, 2018
Bristol-Myers Squibb Company (NYSE:BMY) announced the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) updating the Opdivo ® (nivolumab) dosing schedule to include 480 mg infused every four weeks (Q4